ARB 101A
Alternative Names: ADC-001 - Arbele; ARB-101ALatest Information Update: 09 Oct 2023
At a glance
- Originator Arbele
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Gastrointestinal cancer
Most Recent Events
- 04 Oct 2023 Phase-I clinical trials in Gastrointestinal cancer (Late-stage disease) in an unknown location prior to October 2023 (Parenteral) (Arbele Pipeline, October 2023)
- 06 Jul 2023 Preclinical trials in Gastrointestinal cancer (Late-stage disease) in Hong Kong (Parenteral), prior to July 2023 (Arbele pipeline, July 2023)